• About
  • Partnerships
  • Challenges
  • Awards
  • Grant Opportunities
  • News

Mucosal Delivery and Retention of Anti-HIV Agents Using Lactobacillus

Shi-hua Xiang of the Dana Farber Cancer Institute in the U.S. proposed engineering Lactobacillus, bacteria which normally reside in the human genital and gastrointestinal tract, to carry anti-HIV agents such as neutralizing antibodies, peptides, or other inhibitors. He and his colleagues hypothesized that introducing the engineered bacteria into the gastrointestinal tract would allow the bacteria to colonize and provide long-lasting protection against the virus. This project's Phase I research demonstrated that the engineered anti-HIV Lactobacillus can efficiently block HIV infection in a tissue culture system. In Phase II, Xiang (now at the University of Nebraska) and colleagues are testing this approach in a non-human primate model.

More information about Create New Ways to Prevent or Cure HIV Infection (Round 1)

Great ideas come from everywhere.

Sign up for email updates of the latest grant opportunities and awards.

View the Grand Challenges partnership network

The Bill & Melinda Gates Foundation is part of the Grand Challenges partnership network. Visit www.grandchallenges.org to view the map of awarded grants across this network and grant opportunities from partners.